Illumina, a pharmaceutical speed-reading agency, has made a new discovery in its proposed $8 billion acquisition of GRAIL metformin.

September 22, 2020 / Medical Information List: First-line treatment of esophageal cancer Keytruda chemotherapy combination reduced the risk of death by 27%; Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief Hebei Province issued the third batch of national procurement of selected drugs hanging network notice Hebei Province medical drug equipment centralized procurement center issued on the 21st "on the third batch of state-organized drug centralized procurement of selected drugs in Hebei region of the work of the notice", requiring the third batch of national organizations centralized procurement of selected drugs in Hebei region to declare, The specifications and packaging of selected drugs should be within the scope of the List of Selected Supply Varieties (GY-YD202020-1) in the National Drug Central Procurement, and the third batch of state-organized drugs for centralized procurement of selected drugs in other regions and non-selected drugs of the same variety may also be declared for sale on the Internet in Hebei Province.
(Hebei Province Medical Drug Equipment Centralized Procurement Center) Heilongjiang Province issued the third batch of national procurement of selected drugs hanging network notice 21, Heilongjiang Provincial Health Insurance Bureau issued "on the third batch of national organizations to carry out centralized procurement of selected drugs related to the work of the network", requiring the third batch In the results of the national selection in Heilongjiang Province, the selection and supply of list drugs in accordance with the selected price directly hung on the network, the selected drugs have been registered in the production enterprises also need to participate in the hanging network, the original common name of the winning bid (hanging net) drugs in the results of the implementation of the cease trading qualification.
,000-dollar acquisition of GRAIL Illumina and GRAIL jointly announced that a final agreement had been reached and Illumina would buy GRAIL for $8 billion in cash and stock.
acquisition will accelerate the development of transformative multi-cancer early screening tests, which are expected to lead to earlier cancer diagnosis and better clinical outcomes for patients.
(Pharmaceutical Mingkangde) pre-bio-created board listing pre-bio-listed in the pre-compulsion board today, the issue price of 11.69 yuan, the issue of 105 million shares, raising a total of 1.227 billion yuan.
opened today at 29.5 yuan, up 152% from its offering price.
, the share price has risen, with a market capitalisation of more than $14 billion.
(Sina Pharmaceutical News) Yunding Xinyao IPO through the Hong Kong Stock Exchange hearing 20, the Hong Kong Stock Exchange announced that Yunding Xinyao has been through the Hong Kong Stock Exchange hearing.
filed for an IPO under Chapter 18A of the HKEx Listing Rules in July this year.
four years since its instanceance, Yunding Xinyao has completed a total of $420 million in three rounds of financing and has built a rich pipeline in the pipeline, including eight potentially world-first or best-in-class molecular combinations.
plans to raise $86 million through an IPO to advance the company's development of drugs to treat congenital adrenal hyperplus.
most of the drugs currently used to treat congenital adrenal hyperplosy are steroids that affect the patient's adrenal glands.
and Spruce'stildacerfont, a non-steroidal drug, is currently undergoing Phase 2 clinical trials.
Shattuck filed for an IPO on Nasdaq, a day before the company filed for an IPO.
a $100 million IPO to advance the company's research and development of new cancer drugs.
Shattuck is developing a new agitant redirect checkpoint, and the company's main candidate drug, SL-172154, is currently conducting phase 1 clinical studies related to ovarian cancer, with preliminary data expected to be released in the second half of next year.
company's other drug candidate, SL-279252, is also undergoing Phase 1 clinical trials of advanced solid tumors and lymphomas.
submitted an IPO application to Kronos, which is submitted to NASDAQ.
this filing for a $100 million IPO will be used to advance a phase 2/3 clinical trial of the company's candidate drug, entospletinib, and induced chemotherapy to treat acute myeloid leukemia in patients with NPM1 mutations.
, the funding will also advance phase 1/2 clinical trials of the drug KB-0742 for the treatment of advanced solid tumors.
(Tsing Jianhui) Kyushuan acquisition step subsidiary 21, step-by-step pharmaceutical issued a progress announcement, in order to optimize the company's asset structure, step-by-step pharmaceutical review and adoption of the "on the company's proposed transfer of controlling subsidiary shares of the bill", agreed to the holding subsidiary of Hubei step-by-step Kyushua to transfer 51% of the shares to Kyushua Tong for 21.752 million yuan.
the completion of this industrial and commercial changes, Hubei Kyushua Tong will no longer be included in the scope of the step consolidation report, which means that Kyushua Tong officially obtained control of Hubei step Kyushua Tong, the transfer work is basically completed.
(Seber Blue) Murray's latest layout announced on the 20th, Myer Medical released the "Investor Relations Activity Record Sheet", announced the latest layout in the field of minimally invasive surgery.
based on its strengths in equipment development and marketing models, the company has chosen hard mirror systems, its core products in the field of minimally invasive surgery, as the entry point, and has now launched two laparoscopic systems, HD and 4K.
(Cypress Blue Device) Part 3 drug information first-line treatment of esophageal cancer Keytruda chemotherapy combination reduced the risk of death by 27% Mercedon announced the results of a key Phase 3 clinical trial called KETNOTE-590.
in this randomized double-blind clinical trial, patients with localized advanced or metastatic esophageal cancer were treated with a combination therapy consisting of Keytruda and platinum-containing chemotherapy, or a combination therapy consisting of placebo and platinum-containing chemotherapy.
at 10.8 months, the first interim analysis showed that Keytruda combination therapy reduced the risk of death by 27 percent compared to chemotherapy.
(Pharmaceutical) Opdivo combination therapy reduces the risk of death by 20% BMS has published the results of the latest clinical trial of Opdivo-based combination therapy, in a randomized, open-label Phase 3 clinical trial called CheckMate-649, non-HER2 Patients with positive advanced or metastatic gastric cancer, gastroesophageal connecting cancer, or esophageal adenocarcinoma received a combination therapy consisting of the PD-1 inhibitor Opdivo with chemotherapy, a combination therapy consisting of Opdivo and Yervoy, or chemotherapy.
in all patients, Opdivo's combination therapy with chemotherapy reduced the risk of death by 20 percent.
(Pharmaceutical Minder) Seattle Antibody Association Drug Key Clinical Outcomes Positive Seattle and Genmab presented key Phase 2 clinical trial data for their innovative antibody conceding drug tisotumab vedotin as a single drug therapy to treat patients with relapse and/or metastatic cervical cancer at the ESMO 2020 Virtual Conference.
these patients have underwent double chemotherapy, or beval monotherapy as a first-line therapy.
test results showed that tisotumab vedotin achieved an objective mitigation rate of 24%, with a medium remission duration of 8.3 months.
(Pharmaceutical Mingkangde) "first-in-class" monoclonal antibody initiated Phase 1 clinical trial therapy AML, Immune-Onc announced that the company developed targeted white blood cell immunoglobulin-like subject B4 (LILRB4) in-research therapy IO-202, has completed the first patient in Phase 1 clinical studies.
phase 1 clinical dose increment and amplification trial will evaluate the efficacy of IO-202 in treating patients with acute myeloid leukemia with monocyte differentiation and patients with chronic granulocyte leukemia.
IO-202 is a "first-in-class" monoclonal antibody that blocks the signaling of the immunosuppressive liLRB4.
(Drug Mingkangde) Lilly Abersili reduced the risk of recurrence of HR-HER2-high-risk early breast cancer patients by 25% 20, Lilly Pharmaceuticals announced that Abesili joint standard assisted endocrine therapy for hormone-positive (HR-plus), human dertic growth factor liposuctor 2 negative (HER2-) high-risk early breast cancer patients, compared to the use of standard assisted ET significantly reduced the risk of breast cancer recurrence by 25%.
in all preset subgroups, patients consistently showed statistically significant benefits, with a difference of 3.5% between groups after 2 years of treatment.
(Medical Rubik's Cube) Amed KRAS inhibitor full Phase I data published in the top medical journal NEJM on the 20th, Amsin published Sotorasib's full Phase I (for patients with late-stage solid tumors with KRASG12C mutation) trial results.
showed no dose-limiting toxic effects or treatment-related deaths in terms of safety, and in terms of efficacy, anti-cancer activity was visible in all dose groups in the non-small cell lung cancer queue.
data show that Sotorasib showed encouraging anti-cancer activity in patients with advanced solid tumors with KRASG12C mutations.
(Pharmaceutical Rubik's Cube) Roche Beva Pearl single anti-injection liquid glioblastoma adaptation was approved on the 21st, Roche announced that NMPA approved Beva Pearl single anti-injection for the treatment of adult relapsed glioblastoma patients.
At present, Beval bead monoantin has been approved in China for the treatment of metastatic colorectal cancer, as well as non-removable advanced, metastatic or reoccessive non-squamous cell non-small cell lung cancer patients first-line treatment.
(Bio Valley) Lilly reversible BTK inhibitors for the first time in China declared clinical CDE latest publicity, Lilly in China submitted a class 1 new drug LOXO-305 clinical trial application, and was accepted today.
LOXO-305 is a highly specific, non-co-priced BTK inhibitor developed by Loxo.
2019, Lilly bought Loxo for about $8 billion and acquired a range of new drugs, including LOXO-305.
is the first time the drug has been declared clinical in China.
(CDE) Cinda Bio and Lilly Combined Therapy has been approved for clinical CDE publicity, Lilly developed VEGFR2 antagonist ramucirumab and Cinda BioPD-1 antibody Xindili monoanti-injection therapy obtained clinical trial implied permission to develop a treatment for the first line of non-removable local late stage or metastatic gastric and gastroesophageal junction adenocarcinoma.
(CDE) Fosun Pharma over 100 million yuan of imported products were approved clinical 21, CDE publicity, Fosun Pharma super billion yuan of the introduction of injection DaxibotulinumtoxinA to obtain clinical trials implied permission, intended to develop for medium-heavy eyebrow tattoos.
This is a long-acting neuromodulating device that has previously achieved positive top-line results in two key Phase 3 clinical trials, significantly reducing the severity of moderate to severe eyebrow lines and being safe and well-to-do.
(CDE) and then submitted to Thepotrectinib clinical application CDE official website 21, re-Ding Pharmaceuticals submitted a new drug clinical application for Thepotrectinib capsule, has been accepted by CDE contractor, this broad-spectrum new generation of tyrosine kinase inhibitors opened the research process of China Clinical Center.
(CDE) and platinum pharmaceutical oncology immunotherapy candidates were approved two clinical 21st, and Platinum Pharmaceuticals announced that NMPA has approved its research product anti-CTLA-4 all-human single-source mono-chain antibody HBM4003 two clinical trial applications: HBM4003 monopharmaceutical therapy and regenerant biological anti-PD-1 antibody Terepri monoantigen therapy.
, HBM4003 had been approved for clinical trials in the United States and successfully completed the first phase 1 clinical trial in Australia by the end of 2019.
(Pharmaceutical Mission) Tianji Biotherapy Recurrence or Resuscable Late Lymphoma TJC4 was approved by NMPA clinical trial 21, Tianji Bio announced its use in the treatment of patients with relapsed or resuscable advanced lymphoma in the research of the new drug lemzoparlimab (also known as TJC4) approved by NMPA for Phase 1 clinical trials.
this is the first international multi-center clinical trial approved by lemzoparlimab in China and the second new drug application approved for clinical research in China.
(American News Agency) to Ling Pharmaceutical Lianhua Qing plague capsules by the Mauritian Chinese medicine registration approval to Ling Pharmaceuticals issued a notice that recently, the company received the Mauritius Ministry of Health and Health approved the issuance of the chinese medicine registration approval documents, approved the company's pharmaceutical Lianhua Qing plague capsules in accordance with the Mauritius Chinese medicine standard registration.
even flower plague products for the company's leading products, the national basic drug catalog and the national health insurance directory (Class A) varieties, mainly used for the treatment of colds, influenza-related diseases.
(Eling Pharmaceuticals Announcement) The European Union issued a number of positive comments on drug reviews related to AZ/Mercadon Lynparza... On the 21st, the European Medicines Agency's Committee on Human Pharmaceutical Products issued a number of positive comments on drug reviews, recommending approval in the European Union of AstraZenecom/Mercadon Lynparza joint beval monoantitor for first-line maintenance therapy for patients with progenitor recombinant defects-positive advanced ovarian cancer, Roche anti-P The D-L1 therapy Tecentriq is used in combination with Avastin to treat adult patients with non-removable or metastatic hepatocellular carcinoma who have not previously received systematic treatment, as well as alexion company ULTOMIRIS® a new 100 mg/mL intravenously improved formula.
(Sina Pharmaceutical News) Metformin and new findings Recently, a study from a South Korean research team showed that data from more than 730,000 people found that taking aspirin, statins and metformin were all significantly negatively associated with lung cancer risk, while those taking the drug were at lower risk.
study suggests that aspirin, metformin and statins are independently associated with reduced lung cancer risk and may have synergies.
(Seber Blue)